You have read all your free articles, to continue reading subscribe to read the rest of this content.
Isofol Medical has announced that neither the primary endpoint of Overall Response Rate (ORR) nor the key secondary endpoint in Progression Free Survival (PFS) achieved statistical significance in the multi-center, international Phase III AGENT Study of arfolitixorin in combination with 5-FU, oxalipAlready a subscriber Login You have read all your…
AstraZeneca and MedImmune announce results from their Phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least two prior treatments. This randomised, open-label, multi-centre trial assessed the efficacy and safety of the Already a subscriber Login You have read all…
The Swedish authority is initating an inspection of research projects of five pharmaceutical companies. The Data Inspection Board will among other things investigate how the companies inform participants about how their personal information will be handled and getting their approval to register tAlready a subscriber Login You have read all…
Swedish Orphan Biovitrum (Sobi) and Bioverativ have announced that results from the Kids B-LONG Phase 3 clinical trial, which studied Alprolix in previously-treated children with severe haemophilia B. The primary outcome measure of the trial was development of inhibitors, and no patients treated Already a subscriber Login You have read…
